

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

ADVANCES IN THE PATHOGENESIS AND IMMUNE THERAPIES OF LIVER CANCER

Dec 6–8 | Austin, TX

AACR American Association for Cancer Research

2603026

POSTER LISTING

A001, **SPATIAL TRANSCRIPTOMICS TO CHARACTERIZE METASTATIC CELLS IN PATIENT AND PDX MODELS OF HEPATOBLASTOMA**
Nicholas A O'Brien, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, United States

A002, **LONG-TERM SURVIVAL AFTER LIVER TRANSPLANTATION FOR FIBROLAMELLAR CARCINOMA: A 20-PATIENT INTERNATIONAL COHORT**
Paul Kent, FibroFighters Foundation, River Forest, IL, United States

A003, **LIMITED ACTIVITY OF IPILIMUMAB PLUS NIVOLUMAB IN FIBROLAMELLAR CARCINOMA: REAL-WORLD EXPERIENCE FROM THE FIBROFIGHTERS REGISTRY**
Paul M Kent, FibroFighters Foundation, River Forest, IL, United States

A004, **Tocilizumab enables immune checkpoint inhibitor continuation during severe irAEs in fibrolamellar carcinom**
Paul M Kent, FibroFighters Foundation, Temecula, CA, United States

A005, **GEMCITABINE, OXALIPLATIN, LENVATINIB AND NIVOLUMAB (GOLN) IN ADVANCED FIBROLAMELLAR CARCINOMA: PRELIMINARY REAL-WORLD OUTCOMES FROM THE THE FIBROFIGHTERS REGISTRY**
Paul M Kent, FibroFighters Foundation, River Forest, IL, United States

A006, **Development of a universal shared cancer antigen cocktail mRNA vaccine for postoperative HCC recurrence prevention and CAR/TCR-T cell therapies for advanced and recurrent HCC**
Tetsuya Nakatsura, National Cancer Center Japan, Kashiwa, , Japan

A007, **Physics-Informed Neural Network of Longitudinal Circulating Tumor DNA and Perfusion Kinetics Forecasts Therapeutic Response in Advanced Hepatocellular Carcinoma**
Shivi Kumar, University of Pennsylvania CHOP, Philadelphia, PA, United States

A008, **A Novel Computational Fluid-Dynamics and Machine-Learning Model Predicts Surgical Resection Margins and Immunotherapy Response in Hepatocellular Carcinoma**
Shivi Kumar, University of Pennsylvania CHOP, Philadelphia, PA, United States

A009, **Spatial Transcriptomic and Clonal Evolution Modeling Identifies High-Risk Resection Margins and Predicts Post-Operative Response to Checkpoint Blockade in Hepatocellular Carcinoma**
Shivi Kumar, University of Pennsylvania CHOP, Philadelphia, PA, United States

A010, **Multi-Scale Computational Fluid-Dynamics and Agent-Based Framework Optimizes Surgical Resection Margins and Forecasts Adjuvant Immunotherapy Response in Intermediate Hepatocellular Carcinoma**
Shivi Kumar, University of Pennsylvania CHOP, Philadelphia, PA, United States

A011, **Sphingosine kinase 2-mediated reprogramming of liver macrophages promotes hepatocellular carcinoma initiation and progression**
Sumit Saha, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States

A012, **Large language model-guided CAR-T in silico platform identifies IL-15 to enhance therapy for antigen-low liver cancer**
Yan-Ruide Li, University of California, Los Angeles, Los Angeles, CA, United States

A013, **Therapeutic expansion of peripheral blood MAIT cells enables MR1-dependent immunotherapy for hepatocellular carcinoma**
Yan-Ruide Li, University of California, Los Angeles, Los Angeles, CA, United States

A014, **Adoptive Mucosal-associated invariant T cell therapy for liver cancer enhanced by multimodal modulation of immune receptors and checkpoints**
Yan-Ruide Li, University of California, Los Angeles, Los Angeles, CA, United States

A015, **Generation of anti-Frizzled 7 modulators to inhibit Wnt signaling pathway-dependent cancers**
Issam Hmila, Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Ben Khalifa University (HBKU), Qatar Foundation (QF), Doha Qatar, Doha, , Qatar

A016, PR001 **Spatial profiling reveals distinct immune and angiogenic mechanisms of response and resistance to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma**
Anna Vila-Escoda, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, , Spain

A017, **Spatial profiling of tertiary lymphoid structures identifies cellular networks and microbiome composition associated with immunotherapy response in advanced hepatocellular carcinoma**
Dylan James Crawshaw, Liver Cancer Translational Research Group - IDIBAPS, Liver Unit - Hospital Clínic, Universitat de Barcelona, Barcelona, , Spain

A018, PR003 **TGFβ-targeting with anti-GARP reverts immune suppression and prolongs survival in an experimental MASH-HCC murine model resistant to anti-PDL1+anti-VEGFA therapy.**
Júlia Huguet-Pradell, Icahn School of Medicine at Mount Sinai; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic., New York City, NY, United States

A019, **Cirrhotic MASLD-HCC, but not non-cirrhotic, exhibit immunosuppressive traits with dismal outcomes in atezolizumab plus bevacizumab treatment**
Albert Gris-Oliver, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, , Spain

A020, **CAF positivity is associated with TGF-β signaling, atezolizumab-bevacizumab resistance and poor survival in advanced HCC**
Guillem Cano-Segarra, Liver Cancer Translational Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Facultat de Medicina i Ciències de la Salut, Universita, New York City, NY, United States

A021, **Inhibition of HIF-2α-dependent transcription with casdatifan for the treatment of hepatocellular carcinoma**
Kelsey E Sivick, Arcus Biosciences, Inc., Hayward, CA, United States

A022, **The oncogenic co-driver determines whether β-catenin driven immune exclusion is transient or permanent in hepatocellular carcinoma**
Subash Khadka, UT San Antonio, San Antonio, TX, United States

A023, **In silico subclonal VAF deconvolution predicts emerging resistance pathways to combination VEGFR/PD-1 inhibition in advanced hepatocelluar carcinoma**
Krithik Mudda, Illinois Mathematics and Science Academy, Aurora, IL, United States

A024, **Expression pattern of Glypican-3 (GPC3), a diagnostic and therapeutic target in hepatocellular carcinoma, by clinical and demographic factors**
Bridget Keenan, University of California San Francisco, San Francisco, CA, United States

A025, **TYRA-430: Dual FGFR4/FGFR3 inhibition in hepatocellular carcinoma**
Fernando J. de Miguel, TYRA Biosciences, Carlsbad, CA, United States

A026, **Self-Delivering Antisense-Mediated STEAP2 Silencing Links Labile Copper and Iron Depletion to Suppression of TGF-β/SMAD Signaling and Tumor Progression**
Nagesh N Panchal, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States

A027, **A physiologically relevant 3D metabolic screening platform identifies and prioritizes therapeutic vulnerabilities in hepatocellular carcinoma**
Dzeneta Halilovic, University of Luxembourg, Esch-sur-Alzette, , Luxembourg


A028, **A cellular therapy barrier framework defines distinct resistance architectures in hepatocellular carcinoma**
Khaoula Mazouzi, MD Anderson Cancer Center, Houston, TX, United States

A029, **Neurologic Safety Signals of Immune Checkpoint Inhibitor Regimens in Hepatocellular Carcinoma: A FAERS Pharmacovigilance Study**
Salma Abdel Wahed, The Hashemite University, Zarqa, , Jordan

A030, **MASH enhances HCC immunosurveillance**
Anthony Lozano, Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Immunology and immunotherapy, Tisch Cancer Institute, The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai,, New-York, NY, United States

A031, PR005 **Investigating the Role of Akt Isoforms in MASH- induced Hepatocellular Carcinoma and Liver Fibrosis**
Manahil Ghazi, University of Illinois in Chicago, Chicago, IL, United States

A032, **Progressive loss of non-canonical hepatocyte drivers APOB and ACVR2A across the cirrhosis-to-HCC continuum coincides with TGF-beta stromal remodeling and is dissociated from TP53-driven clonal expansion**
Naga Sriharsha Mudda, Illinois Mathematics and Science Academy, Aurora, IL, United States



A033, **AKT1 and AKT2 in PTEN-deficient liver cancer: from tumor phenotype to isoform-specific signaling**
Ielyzaveta Slarve, University of Southern California, Los Angeles, CA, United States

A034 **Decoding Macrophage Heterogeneity and Clinical Outcomes in Hepatocellular Carcinoma**
Venkata Siva Ramisetty, University of California, Los Angeles, Sunnyvale, CA, United States


A035, **Metabolic Reprogramming in MASH-Related HCC:The Emerging Role of G6PD as a Biomarker and Target**
Jessica Nurcis, University of Turin, Turin, , Italy

A036, **From fibrogenesis to immune evasion: TREM1 as a master regulator of Kupffer cell activation and MDSC-driven immunosuppression, and its inhibition as a therapeutic strategy in hepatocellular carcinoma**
Ashwin Ajith, Georgia Cancer Center, Augusta University, Augusta, GA, Augusta, GA, United States

A037, **Hepatocyte SHMT2 drives MASH-associated HCC via one-carbon mediated regulation of nucleotide biosynthesis**
Jemiah K Pascua, LSU Health Shreveport, Shreveport, LA, United States

A038, **Entosis contributes to loco-regional therapy resistance in hepatocellular carcinoma**
Evan Fitzgerald, University of Pennsylvania, Philadelphia, PA, United States

A039, **Loss of the nuclear envelope protein LAP1/Tor1aip1 drives genome-wide DNA hypomethylation linking steatosis and genomic instability in mouse hepatocytes**
Andy Madrid, Hackensack Meridian Health, Nutley, NJ, United States



A040, **ID1 loss attenuates metabolic dysfunction-associated steatohepatitis and identifies a targetable Kupffer cell pathway**
Riddhi Shah, Sun Pharma Advanced Research Company, Mumbai, , India

A041, **Immune and inflammatory protein signatures underlying hepatocarcinogenesis in chronic hepatitis B infection**
VÉRONIQUE SIDNOOMA ZONGO, Université Joseph Ki ZERBO, Ouagadougou, , Burkina Faso

A042, **Nitrogen metabolism in hepatocellular carcinoma**
Wei-Xing Zong, Rutgers University, Piscataway, NJ, United States

A043, **Development of an HCC Cell Model with Defined Driver Alterations from Primary Human Hepatocytes**
Lobna Elkhadragy, University of Illinois Chicago, Chicago, IL, United States

A044, **Targeting creatine metabolism as a therapeutic vulnerability in hepatocellular carcinoma**
Lobna Elkhadragy, University of Illinois, Chicago, IL, United States

A044, **Mutant IDH1 sustains an epigenetically defined malignant cell state and therapeutic resistance in intrahepatic cholangiocarcinoma**
Haley Ellis, Mass General Brigham Cancer Institute, Boston, , United States

A045, **Targeting P38 MAPK and Rho-A Pathways in Hepatocellular Carcinoma: The Pro-apoptotic and Anti- metastatic Potential of the Curcumin Analog BHMC.**
Abeer Raslan Shaban, Al Ahliyah Amman University, Salt, , Jordan

A046, **Immune tumor suppressor gene discovery and its suppression mechanism**
Shulin Li, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

A047, **Effects of endogenous alcohol in carcinogenesis process of hepatocellular carcinoma**
Aurelian Udristioiu, Titu Maiorescu University of Bucharest, Faculty of General Assistance, City Targu Jiu, Romania, City Targu Jiu, , Romania


A048, **Transcriptomic Signatures Associated with Fibrosis Progression in MASLD Highlight Molecular Features of the Fibrotic Liver Microenvironment**
Karla Perez, University of Texas Rio Grande Valley, McAllen, TX, United States

A049, **Design, synthesis, and computational prioritization of pyridine-based heterocyclic derivatives as potential EGFR-targeted anticancer agents**
MOHD AATIF JAMIL AHMED SHAIKH, JAMIA HAMDARD UNIVERSITY, New Delhi, , India

A050, **Environmental hepatotoxicity and carcinogenesis: Mechanisms, modifiers, and global health implications**
Dhanush Bearelly, Virginia Commonwealth University, Richmond, VA, United States

A051, PR002 **Immune checkpoint B7-H4 drives stromal remodeling and cholangiocarcionma growth**
Emily R Bramel, Icahn School of Medicine at Mount Sinai, New York, NY, United States

A052, PR004 **Targeting macrophage-derived CXCL5 enhances the response to PD-1 blockade in hepatocellular carcinoma**
Diala alhousari, University of Southern California, Los Angeles, CA, United States



AACR SPECIAL CONFERENCE IN CANCER RESEARCH
ADVANCES IN THE PATHOGENESIS AND IMMUNE THERAPIES OF LIVER CANCER
Dec 6-8 | Austin, TX
AACR American Association for Cancer Research
2603026

A053, **Synergistic Prognostic Value of the Systemic Immune-Inflammation Index (SII) and De Ritis Ratio in Hepatocellular Carcinoma Undergoing Immune Checkpoint Inhibition: A Systematic Evidence Synthesis**

Debanjan Gangopadyay, Brainware University, Barasat, , India

A054, **Effect of Immunomodulatory Ayurveda Rasayana therapy in improving outcomes of conventional anticancer therapy in refractory patients of Hepatocellular carcinoma (HCC): A retrospective analysis of clinical outcomes and predictors of response**

Eeshani Bendale, Rasayu Cancer Clinic, Pune, , India